Now showing items 11-20 of 22
Encouraging innovative treatment of neglected diseases through priority review vouchers
(Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, 2009-09-01)
Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act
(International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, 2005)
Distinguished economists, political scientists, and legal experts discuss the implications of the increasingly globalized protection of intellectual property rights for the ability of countries to provide their citizens ...
'Price and Profit Control, New Competitive Dynamics and the Economics of Innovation in the Pharmaceutical Industry'
(Industrial Policy and the Pharmaceutical Industry, 1995)
Innovation and International Competitiveness in Pharmaceuticals
(Evolving Technology and Market Structure: Studies in Schumpeterian Economics, 1990)
Pressures from the Demand Side: Changing Market Dynamics and Industrial Structure
(Consolidation and Competition in the Pharmaceutical Industry, 2001)
The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982-2003
(Incentives for Research, Development, and Innovation in Pharmaceuticals, 2012-08-09)
The Pharmaceutical Industry
(Government and Technical Progress, 1982)
Competition between Generic and Branded Drugs
(Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective, 2007-04-30)
The pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gross domestic product and employment. Technological change in this field has been very rapid, with many new products being ...
R&D Costs and Returns to New Drug Development: A Review of the Evidence
(The Oxford Handbook of the Economics of the Biopharmaceutical Industry, 2012-09-18)
© 2012 by Oxford University Press. All rights reserved.This article reviews the extensive literature on R&D costs and returns. The first section focuses on R&D costs and the various factors that have affected the trends ...
FDA in the Twenty-First Century
(FDA Regulation Of Biosimilars, 2015)